RS-1 - RAD51-Stimulatory Compound-1

RS-1 - RAD51-Stimulatory Compound-1 - Names and Identifiers

Name	4-Bromo-N-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]benzamide
Synonyms	RS1 RS 1 RS-1 CS-2312 RAD51-stimulatory compound 1 RAD51-Stimulatory Compound-1, RS-1 RS-1 - RAD51-Stimulatory Compound-1 3-benzylsulfamoyl-4-bromo-N-(4-bromophenyl)benzamide 4-BroMo-N-(4-broMophenyl)-3-[[(phenylMethyl)aMino]sulfonyl]benzaMide 4-Bromo-N-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]benzamide
CAS	312756-74-4
InChIKey	VBOWCZDVEOFGRY-UHFFFAOYSA-N

RS-1 - RAD51-Stimulatory Compound-1 - Physico-chemical Properties

Molecular Formula	C20H16Br2N2O3S
Molar Mass	524.23
Solubility	DMSO: ≥10mg/mL
Appearance	powder
Color	off-white to light tan
Storage Condition	room temp
Stability	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Physical and Chemical Properties	Biological activity RS-1 is a compound that stimulates rad51. Can increase the DNA binding activity of rad51. In vitro and in vivo experiments with rabbit embryos, RS-1 enhanced Cas9 and TALEN-mediated knock-in efficiency.
Use	Application 4-bromo-n-(4-bromophenyl)-3-[[(phenylmethyl) amino] sulfonyl] benzamide is an intermediate in organic synthesis and pharmaceutical intermediates, can be used in laboratory development processes and chemical production processes.
Target	Target Value RAD51
In vitro study	RS-1 stimulates the binding of hRAD51 to ssDNA. A concentration of RS-1 on the micromolar scale enhances DNA binding and results in an extension of the length of the protein-DNA complex. In addition, RS-1 stabilizes the activated form of hrad51. In vitro and in vivo experiments with rabbit embryos, RS-1 enhanced Cas9 and TALEN-mediated knock-in efficiency.

RS-1 - RAD51-Stimulatory Compound-1 - Risk and Safety

Hazard Symbols	Xi - Irritant
Risk Codes	36 - Irritating to the eyes
Safety Description	26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany	3

RS-1 - RAD51-Stimulatory Compound-1 - Preparation solution concentration reference

	1mg	5mg	10mg
1 mM	1.908 ml	9.538 ml	19.076 ml
5 mM	0.382 ml	1.908 ml	3.815 ml
10 mM	0.191 ml	0.954 ml	1.908 ml
5 mM	0.038 ml	0.191 ml	0.382 ml

Last Update：2024-01-02 23:10:35

RS-1 - RAD51-Stimulatory Compound-1 - Introduction

4-Bromo-N-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]benzamide is an organic compound with the following properties:

1. Appearance: White crystalline solid.
2. Molecular formula: C14H10Br2N2O3S.
3. Molecular weight: 436.12g/mol.
4. Melting point: 170-172 degrees Celsius.
5. Solubility: Soluble in some organic solvents (such as chloroform, methanol).

The main uses of this compound are:

1. As a pharmaceutical intermediate: it can be used to synthesize biologically active compounds, such as drugs, pesticides, etc.
2. As a dye intermediate: It can be used as an important intermediate in dye synthesis.

The method of preparing 4-Bromo-N-(4-bromophenyl)-3-[[(phenyl methyl)amino]sulfonyl]benzamide includes the following steps:

1. The reaction of phenyl formyl chloride and aniline to generate sulfinate compounds.
2. The sulfinate compound is reacted with hydrobromic acid to generate 4-bromo-n-(4-bromophenyl)-benzamide.
3. Reaction of 4-Bromo-N-(4-bromophenyl)-benzamide with benzyl alcohol yields 4-Bromo-N-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]benzamide.

The following safety information is required when using and handling this compound:

1. This compound may be irritating and corrosive to the eyes, skin and respiratory tract, so appropriate protective measures are required during handling and contact, including wearing protective glasses, gloves and protective masks.
2. Avoid inhaling its dust or gas, and use ventilation equipment when necessary.
3. Avoid exposure to the compound while eating, drinking or smoking.
4. When using this compound, laboratory practices and safe operating procedures should be followed.
5. In the event of an accident or accidental ingestion, seek medical help immediately and provide the safety data sheet of the compound to the medical staff for reference.

Last Update：2024-04-09 21:21:28